Loading...
By Kelly Young
Edited by Susan Sadoughi, MD
The FDA has approved alirocumab (Praluent) as an adjunctive therapy to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (e.g., myocardial infarction or stroke) who have not been able to lower their LDL sufficiently on statins.
Alirocumab is the first approved drug that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9). This ultimately helps liver receptors remove LDL from the blood. The injectable drug is intended to be used in concert with diet, exercise, and the maximally tolerated dose of statins.
In five clinical trials of patients with HeFH or cardiovascular disease who were already taking statins, alirocumab was associated with a 36% to 59% mean reduction in LDL levels relative to placebo.
Common adverse events include itching, swelling, pain, or bruising at the injection site; nasopharyngitis; and flu. In addition, patients have reported allergic reactions, including hypersensitivity vasculitis, and hypersensitivity reactions that required hospitalization.
Comment
LINK(S):
FDA news release (Free)
Background: Physician's First Watch coverage of FDA advisory panel recommending approval of alirocumab (Free)
Background: NEJM Journal Watch Cardiology coverage of alirocumab trial (Free)